Keybank National Association OH Boosts Position in DexCom, Inc. (NASDAQ:DXCM)

Keybank National Association OH lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 101.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,585 shares of the medical device company's stock after buying an additional 8,853 shares during the quarter. Keybank National Association OH's holdings in DexCom were worth $1,368,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Versant Capital Management Inc bought a new stake in DexCom in the fourth quarter worth $25,000. Private Trust Co. NA increased its position in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in DexCom in the fourth quarter worth $38,000. SBI Securities Co. Ltd. bought a new stake in DexCom in the fourth quarter worth $49,000. Finally, Midwest Capital Advisors LLC bought a new stake in DexCom in the fourth quarter worth $54,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Down 2.1 %

Shares of DXCM traded down $1.67 during mid-day trading on Friday, hitting $77.84. 3,861,055 shares of the company traded hands, compared to its average volume of 3,717,810. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $30.42 billion, a PE ratio of 54.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The business has a 50 day moving average of $84.83 and a 200 day moving average of $76.99.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DXCM. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company boosted their price objective on shares of DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and upped their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Citigroup upped their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock worth $3,309,794 in the last quarter. Company insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.